Theranostics of Thyroid Cancer

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-07-01 DOI:10.1053/j.semnuclmed.2024.01.011

{"title":"Theranostics of Thyroid Cancer","authors":"","doi":"10.1053/j.semnuclmed.2024.01.011","DOIUrl":null,"url":null,"abstract":"<div>Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie, I131, I123, I124) is a central component of differentiated carcinoma (DTC)'s risk stratification while [18F]F-fluorodeoxyglucose ([18F]FDG) PET/CT is interrogated about disease aggressiveness and presence of distant metastases. Moreover, it is particularly useful to assess and risk-stratify patients with radioiodine-refractory DTC, poorly differentiated, and anaplastic thyroid cancers. [18F]F-dihydroxyphenylalanine (6-[18F]FDOPA) PET/CT is the most specific and accurate molecular imaging procedure for patients with medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells. In addition, [18F]FDG PET/CT can be used in patients with more aggressive clinical or biochemical (ie, serum markers levels and kinetics) MTC phenotypes. In addition to conventional radioiodine therapy for DTC, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC. Moreover, peptide receptor theranostics showed promising results in patients with advanced and metastatic radioiodine-refractory DTC and MTC, respectively. The current appropriate role and future perspectives of molecular imaging and theranostics in thyroid cancer are discussed in our present review.</div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000114","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie, I¹³¹, I¹²³, I¹²⁴) is a central component of differentiated carcinoma (DTC)'s risk stratification while [¹⁸F]F-fluorodeoxyglucose ([¹⁸F]FDG) PET/CT is interrogated about disease aggressiveness and presence of distant metastases. Moreover, it is particularly useful to assess and risk-stratify patients with radioiodine-refractory DTC, poorly differentiated, and anaplastic thyroid cancers. [¹⁸F]F-dihydroxyphenylalanine (6-[¹⁸F]FDOPA) PET/CT is the most specific and accurate molecular imaging procedure for patients with medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells. In addition, [¹⁸F]FDG PET/CT can be used in patients with more aggressive clinical or biochemical (ie, serum markers levels and kinetics) MTC phenotypes. In addition to conventional radioiodine therapy for DTC, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC. Moreover, peptide receptor theranostics showed promising results in patients with advanced and metastatic radioiodine-refractory DTC and MTC, respectively. The current appropriate role and future perspectives of molecular imaging and theranostics in thyroid cancer are discussed in our present review.

查看原文本刊更多论文

甲状腺癌的血清疗法

分子成像在评估和管理不同甲状腺癌组织类型的患者方面至关重要。通过纳入具有治疗价值的肿瘤特异性分子和分子成像生物标志物，可以对现有的基于病理学的风险分层系统进行有益的改进，从而做出针对患者的治疗决策。使用不同放射性碘同位素（即 I131、I123、I124）进行分子成像是分化型癌症（DTC）风险分层的核心组成部分，而[18F]F-氟脱氧葡萄糖（[18F]FDG）正电子发射计算机断层扫描（PET/CT）则可检测疾病的侵袭性和是否存在远处转移。此外，[18F]F-氟脱氧葡萄糖 PET/CT 对放射性碘难治性 DTC、分化不良和无细胞甲状腺癌患者的评估和风险分级也特别有用。[18F]F-二羟基苯丙氨酸（6-[18F]FDOPA）PET/CT是甲状腺髓样癌患者最特异、最准确的分子成像程序，甲状腺髓样癌是一种源自甲状腺C细胞的神经内分泌肿瘤。此外，[18F]FDG PET/CT 还可用于临床或生化（即血清标志物水平和动力学）表型更具侵袭性的 MTC 患者。除了对 DTC 采用传统的放射性碘治疗外，现在还有新的再分化策略可用于恢复放射性碘难治性 DTC 的摄取。此外，肽受体疗法在晚期和转移性放射性碘难治性 DTC 和 MTC 患者中分别显示出良好的疗效。本综述讨论了分子成像和治疗药物目前在甲状腺癌中的适当作用和未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.